NEW YORK, NY / ACCESSWIRE / October 5, 2017 / Shares of Tetraphase Pharma and Genetic Technologies both climbed higher on Wednesday. Despite any news to serve as a catalyst for the gains, shares of Genetic Technologies closed up over 11%. Shares of Tetraphase closed up nearly 7% after announcing data at IDWeek 2017.
RDI Initiates Coverage on:
Tetraphase Pharmaceuticals, Inc.
Genetic Technologies Limited
Tetraphase Pharmaceuticals, Inc.'s shares closed up 6.90% yesterday on nearly 2.5 million shares traded. The stock soared ahead after the clinical stage biopharma company announced the presentation of data at IDWeek 2017. According to the company's press release, the "presentation was of the company's first study of a recently completed phase 1 program designed to optimize drug exposure of oral eravacycline in an IV-to-oral dosing regimen." Eravacycline is a synthetic fluorocycline antibiotic in development by Tetraphase Pharmaceuticals. It is intended for the treatment of serious infections, including those caused by MDR pathogens.
CEO Guy Macdonald commented, "We are encouraged by the clinical data in healthy volunteers we have recently seen in the phase 1 oral eravacycline development program and are eager to initiate the next step of evaluating the optimized IV-to-oral dosing regimen in a patient population."
"In addition to establishing an oral dosing regimen, this phase 1 program has also confirmed that drug exposures and urine concentrations achieved with IV eravacycline are within the expected therapeutic range and support the efficacy of once-daily IV eravacycline in cUTI, which we are evaluating in the ongoing phase 3 IGNITE3 study. We look forward to topline data for IGNITE3 in the first quarter of 2018."
Access RDI's Tetraphase Pharmaceuticals, Inc. Research Report at:
Genetic Technologies Limited's shares closed up 11.48% on Wednesday with a little over 3 million shares traded. There was no significant news from the company to explain the erratic movement in volume yesterday. It was at the end of last month that the company announced it would be transitioning the commercialization of its BREVAGenplus test to an e-commerce based solution. BREVAGenplus® is a clinically validated risk assessment test for non-hereditary breast cancer. With the new program, consumers can begin testing by accessing the consumer initiated testing (CIT) platform through Genetic Technologies' website: www.brevagenplus.com.
Access RDI's Genetic Technologies Limited Research Report at:
Research Driven Investing
We are committed to providing relevant and actionable information for the self-directed investor. Our research is reputed for being a leader in trusted, in-depth analysis vital for informed strategic trading decisions. The nimble investor can leverage our analysis and collective expertise to execute a disciplined approach to stock selection.
RDInvesting has not been compensated; directly or indirectly; for producing or publishing this document.
Disclaimer: This article is written by an independent contributor of RDInvesting.com and Nadia Noorani, a CFA® charter holder, has provided necessary guidance in preparing the document templates. RDInvesting.com is neither a registered broker-dealer nor a registered investment advisor. For more information please read our full disclaimer at www.rdinvesting.com/disclaimer.
For any questions, inquiries, or comments reach out to us directly at:
Research Driven Investing, Unit #901 511 Avenue of the Americas, New York, NY, 10011
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.